Metyrapone as treatment in the neonatal McCune-Albright syndrome

J Pediatr Endocrinol Metab. 2020 Jul 22:/j/jpem.ahead-of-print/jpem-2020-0036/jpem-2020-0036.xml. doi: 10.1515/jpem-2020-0036. Online ahead of print.

Abstract

Objectives To present a case report of succesfully metyrapone treatment of a neonatal patient with McCune-Albrigth syndrome (MAS), a rare disease caused by a genetically mosaic disorder and is characterized by variable hyperfunctional endocrinopathies, bone dysplasia, and café-au-lait spots. Case presentation A preterm newborn was admitted to hospital and she presented difficulty controlling hypertension, café-au-lait spots, and failure to thrive. An abdominal ultrasound and a magnetic resonance showed a high volume of both suprarenal glands. Therefore, MAS was suspected. Laboratory data confirmed adrenocorticotropic hormone-independent Cushing's syndrome with hepatic dysfunction and metyrapone treatment was initiated. A progressive normalization of cortisol levels was achieved despite poor oral tolerance. Conclusion Our case shows that metyrapone is useful in the management of neonatal Cushing's syndrome due to McCune-Albright syndrome.

Keywords: McCune–Albright syndrome; endocrinology; metabolism; metyrapone; neonatal cushing syndrome; pediatric; pharmacy.

Publication types

  • Case Reports